ORIC insider trading
NasdaqGS HealthcareOric Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Company website: www.oricpharma.com
ORIC insider activity at a glance
FilingIQ has scored 202 insider transactions for ORIC since Apr 24, 2020. The most recent filing in our index is dated Feb 24, 2026.
Across the full history, 11 open-market purchases
and 116 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ORIC insider trades is 62.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ORIC Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ORIC
13F funds holding ORIC
Frequently asked
- How many insider trades does FilingIQ track for ORIC?
- FilingIQ tracks 202 Form 4 insider transactions for ORIC (Oric Pharmaceuticals, Inc.), covering filings from Apr 24, 2020 onwards. 3 of those were filed in the last 90 days.
- Are ORIC insiders net buyers or net sellers?
- Across the full Form 4 history for ORIC, 11 transactions (5%) were open-market purchases and 116 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ORIC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ORIC in?
- Oric Pharmaceuticals, Inc. (ORIC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.31B.
Methodology & sources
Every ORIC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.